Volume 4.41 | Oct 25

Prostate Cell News 4.41 October 25, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Genes Upregulated in Prostate Cancer Reactive Stroma Promote Prostate Cancer Progression In Vivo
Scientists have previously identified genes with diverse functions that are upregulated in reactive stroma. This study tests the hypothesis that expression of these genes in stromal cells enhances prostate cancer growth in vivo. [Clin Cancer Res] Abstract
Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by impact factor of the journal)

A Reciprocal Role of Prostate Cancer on Stromal DNA Damage
Xenografting of human prostate cancer epithelia, LNCaP, resulted in the epigenetic transforming growth factor-beta type II receptor (Tgfbr2) silencing of host mouse prostatic fibroblasts. Stromal Tgfbr2 promoter hypermethylation, initiated by LNCaP cells, was found to be dependent on interleukin 6 expression, based on neutralizing antibody studies. [Oncogene] Abstract

Piperlongumine Inhibits NF-κB Activity and Attenuates Aggressive Growth Characteristics of Prostate Cancer Cells
The authors looked at the effects of piperlongumine, a biologically active alkaloid/amide present in piper longum plant, on the NF-κB pathway in androgen-independent prostate cancer cells. [Prostate] Abstract

Enrichment of Human Prostate Cancer Cells with Tumor Initiating Properties in Mouse and Zebrafish Xenografts by Differential Adhesion
Investigators adapted the collagen adherence feature to develop a combined immunophenotypic and time-of-adherence assay to identify human prostate tumor-initiating cells. [Prostate] Abstract

Development of a Peptide-Based Vaccine Targeting TMPRSS2:ERG Fusion-Positive Prostate Cancer
ERG295 overcame peripheral tolerance in HLA-A*0201 mice that expressed prostate-restricted ERG. Also, this peptide induced an antigen-specific response against ERG-expressing human prostate tumor cells. [Cancer Immunol Immunother] Abstract

Down-Regulation of RE-1 Silencing Transcription Factor (REST) in Advanced Prostate Cancer by Hypoxia-Induced miR-106b~25
Researchers demonstrated that hypoxia promotes neuronal and neuroendocrine differentiation of neural crest cells and prostate cancer cells, respectively, by inducing the microRNA (miR)-106b~25 cluster. [Exp Cell Res] Abstract

Synthesis and In Vitro Characterization of Ionone-Based Compounds as Dual Inhibitors of the Androgen Receptor and NF-κB
Researchers discovered SC97 and SC245 inhibit NF-κB. By synthesizing a series of derivatives of these two compounds, they discovered a novel compound 3b that potently inhibits both androgen receptor (AR) and NF-κB signaling, including the AR F876L mutant. [Invest New Drugs] Abstract

The Tumor Suppressing Effects of QKI-5 in Prostate Cancer: A Novel Diagnostic and Prognostic Protein
Using lentiviral vectors, investigators established two stable prostate cancer cell lines with altered quaking 5 (QKI-5) expression, including a QKI-5 overexpressing PC3 cell line and a DU145 cell line with knocked-down QKI-5 expression. The effects of the lentiviral-mediated QKI-5 knockdown on the PC3 cells and DU145 cells were assessed by cell growth curves, flow cytometry, and an invasion assay. [Cancer Biol Ther] Abstract

Differences in Transport Mechanisms of trans-1-Amino-3-[18F]Fluorocyclobutanecarboxylic Acid in Inflammation, Prostate Cancer, and Glioma Cells: Comparison with L-[Methyl-11C]Methionine and 2-Deoxy-2-[18F]Fluoro-D-Glucose
Using carbon-14-labeled tracers, in vitro time-course, pH dependence, and competitive inhibition uptake experiments were performed in rat inflammatory, prostate cancer, and glioma cells. [Mol Imaging Biol] Abstract


The Prevalence of the HOXB13 G84E Prostate Cancer Risk Allele in Men Treated with Radical Prostatectomy
DNA samples from men treated with radical prostatectomy were genotyped for G84E and confirmed by Sanger sequencing. The frequency and distribution of this allele was determined according to specific patient characteristics. [BJU Int] Abstract

Men (Aged 40-49 Years) with a Single Baseline Prostate-Specific Antigen Below 1.0 ng/mL Have a Very Low Long-Term Risk of Prostate Cancer: Results from a Prospectively Screened Population Cohort
Scientists studied the use of a baseline prostate-specific antigen and digital rectal examination in men in predicting long-term prostate cancer risk in a prospectively followed, representative population cohort. [Urology] Abstract

Detect 7 times more prostate epithelial progenitors with ProstaCult
Non-Coding RNAs in Prostate Cancer: The Long and the Short of It
The authors summarize the growing body of evidence supporting a pivotal role for non-coding RNAs (ncRNAs) in the pathogenesis of prostate cancer. They highlight the most promising ncRNA biomarkers for detection and risk-stratification and present the state-of-play for RNA-based personalized medicine in treating the “untreatable” prostate tumors. [Clin Cancer Res] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.
Medivation and Astellas Announce the Phase III PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients with Advanced Prostate Cancer
Medivation, Inc. and Astellas Pharma Inc. announced that the Independent Data Monitoring Committee has informed the companies of positive results from a planned interim analysis of the global Phase III PREVAIL trial of enzalutamide in more than 1,700 men with metastatic prostate cancer that has progressed despite androgen deprivation therapy and who have not yet received chemotherapy. [Astellas Pharma Inc.]
Press Release

Mesoblast, Intrexon and ZIOPHARM to Target Cancers
Mesoblast Limited, Intrexon Corporation and ZIOPHARM Oncology, Inc. announced a partnership to develop a new class of cancer therapeutics. Under the terms of the agreement the companies will combine Mesoblast’s proprietary Mesenchymal Lineage Cellswith Intrexon’s RheoSwitch Therapeutic System® platform to co-develop complex transgene enabled cell-based treatments for oncology applications. [Mesoblast Limited] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 2013 American Society for Cell Biology (ASCB) Annual Meeting
December 14-18, 2013
New Orleans, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Experienced Researcher Position – Molecular Biology (ServiceXS B.V.)

Postdoctoral Fellow – Mechanisms of DNA Damage in the Development and Progression of Prostate Cancer (Johns Hopkins Hospital)

Senior Postdoctoral Researcher – Signaling and Metabolic Alterations in Prostate and Breast Cancer (CIC bioGUNE)

Research Technician Position – Steroid Receptor Signaling (Baylor College of Medicine)

Postdoctoral Research Associates – Tumor Immune Evasion Mechanism and Inflammation (Hollings Cancer Center)

Postdoctoral Fellow – Prostate Cancer and Head & Neck Cancer (University of Maryland Baltimore)

Postdoctoral Position – Prostate Cancer Biology (University Of Rochester School Of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Prostate Cell News: Archives | Events | Contact Us